$27.95
+3.4%Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
LBRX • NASDAQ
| LB Pharmaceuticals Inc Common Stock Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
ASSETS | ||||
CURRENT ASSETS | ||||
250.2M | 23M | 15M | 21.4M | |
45M | 5M | 28.3M | 0.0 | |
295.2M | 28M | 43.3M | 21.4M | |
2M | 748K | 2.3M | 76K | |
11.2M | 132K | 26K | 9K | |
308.4M | 28.9M | 45.6M | 21.5M | |
NON-CURRENT ASSETS | ||||
3.7M | 4.2M | 23K | 3K | |
770K | 0.0 | 0.0 | 0.0 | |
0.0 | 498K | 0.0 | 0.0 | |
4.5M | 4.7M | 23K | 3K | |
312.9M | 33.5M | 45.7M | 21.5M | |
LIABILITIES | ||||
CURRENT LIABILITIES | ||||
2.1M | 2.3M | 1.4M | 156K | |
2.1M | 2.3M | 1.4M | 156K | |
1.7M | 3.1M | 419K | 92K | |
730K | 0.0 | 0.0 | 0.0 | |
0.0 | 487K | 0.0 | 0.0 | |
2.9M | 2.2M | 798K | 221K | |
7.4M | 8.1M | 2.6M | 469K | |
NON-CURRENT LIABILITIES | ||||
0.0 | 0.0 | 0.0 | 24.1M | |
1.3M | 116.8M | 77.5M | 25.7M | |
4.2M | 120M | 77.5M | 49.8M | |
2.8M | 3.7M | 0.0 | 0.0 | |
11.6M | 128.1M | 80.1M | 50.3M | |
SHAREHOLDERS' EQUITY | ||||
3K | 1K | 1K | 1K | |
430.7M | 9.7M | 6.5M | 6.1M | |
-129.5M | -104.3M | -41.2M | -34.9M | |
168K | 111K | 274K | 0.0 | |
301.3M | -94.6M | -34.5M | -28.8M | |
301.3M | -94.6M | -34.5M | -28.8M | |
SUMMARY | ||||
312.9M | 33.5M | 45.7M | 21.5M | |
45.8M | 5M | 28.3M | 0.0 | |
3.6M | 3.7M | 0.0 | 24.1M | |
-246.6M | -19.3M | -15M | 2.7M | |
22,442,989 | 22,442,989 | 22,442,989 | 22,442,989 |
LBRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 03, 2026 | 2026 | |
S-1 S-1 N/A | April 06, 2026 | April 06, 2026 | ||
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 04, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 10, 2025 | 2025 |
Continue your LBRX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.